Strug­gling Aprea wins a re­prieve as FDA lifts one of the holds on their on­ly drug

A strug­gling Aprea Ther­a­peu­tics got a boost Thurs­day morn­ing af­ter the biotech re­port­ed that the FDA had lift­ed one of the clin­i­cal holds on its one and on­ly drug in the clin­ic.

Re­main­ing tight-lipped as usu­al, Aprea $APRE put out a short state­ment ear­ly to­day say­ing that the hold had been lift­ed on their study of eprene­tapopt with Calquence or with vene­to­clax and rit­ux­imab in lym­phoid ma­lig­nan­cies. The stock jumped more than 10% ahead of the bell, but is down 85% over the past year, leav­ing the mar­ket cap around a weak $90 mil­lion mark.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER